Numerous DZD researchers will present current results of their research at the EASD annual meeting in Hamburg. The outstanding quality of research at the DZD is reflected in the awards presented by the European professional society. Three DZD researchers will be honored this year.

Camillo Golgi Prize for Stephan Herzig
The prize, named after Nobel Prize winner Camillo Golgi, is awarded to honor outstanding contributions in the field of pathogenesis, prevention and treatment of diabetic complications such as non-alcoholic fatty liver, liver fibrosis and cancer. This year, Prof. Dr. Stephan Herzig will be honored with the award. The molecular pharmacologist is scientific director of the Helmholtz Diabetes Center and research director of Helmholtz Munich. There he also heads the Institute for Diabetes and Cancer and coordinates the Research Academy on Diabetic Complications at the DZD.

Stephan Herzig's research contributed to a paradigm shift in the view of diabetic complications: They do not arise in isolation in a single organ, as was long assumed; rather, communication between peripheral metabolic organs plays a role. Key elements of his work have already reached clinical practice. For example, clinical trials are investigating whether fasting programs can serve to control metabolic dysfunction in diabetic patients with chronic kidney disease.

Prize lecture: Tuesday, October 3, 5:15 - 6:15 p.m., Hamburg Hall

© EASD / DZD

Timo Müller receives Minkowski Prize
The EASD awards the Minkowski Prize to researchers whose publications have dramatically increased knowledge about diabetes. This year it is awarded to PD Dr. Timo Müller, Director of the Institute for Diabetes and Obesity at Helmholtz Munich.

The glucose-dependent insulinotropic peptide (GIP) or its receptor in the brain are key targets for reducing body weight and improving glucose control, for example in the form of so-called GIP/GLP-1 co-agonists. Timo Müller was able to show for the first time that GIP reduces body weight and food intake via this receptor in the brain. Müller's studies help to target the GIP system for the development of new obesity drugs, but also contribute to a better understanding of the mechanism of action of this new class of pharmacological therapies.

Award lecture: Thursday, Oct. 5, 5:35 - 6:15 p.m., Hamburg Hall.

Theresia Sarabhai is EASD Rising Star 2023
Each year, EASD selects four young scientist:s to present an overview of their research at a multidisciplinary research symposium. In addition, the young researchers receive a Research Fellowship to promote innovative research in Europe.

This year, Dr. Theresia Sarabhai from the German Diabetes Center (DDZ) is one of the honorees who will have the opportunity to present her research at the EASD Rising Star Symposium. She will also receive the EFSD Rising Star Fellowship. Sarabhai has been selected for the symposium and fellowship program for her research project, "Identification of the early pathogenesis of overeating-mediated insulin resistance in adipose tissue of healthy individuals." The goal of her study is to better understand the development of tissue-specific insulin resistance to help prevent obesity and type 2 diabetes in the future.

To the congress website